
1. plos one. 2016 jul 28;11(7):e0160172. doi: 10.1371/journal.pone.0160172.
ecollection 2016.

variation human cytochrome p-450 drug-metabolism genes: gateway the
understanding plasmodium vivax relapses.

silvino ac(1), costa gl(1), araújo fc(1), ascher db(2)(3), pires de(2), fontes
cj(4), carvalho lh(1), brito cf(1), sousa tn(1).

author information: 
(1)molecular biology malaria immunology research group, centro de pesquisas
rené rachou, fundação oswaldo cruz (fiocruz), belo horizonte, minas gerais,
brazil.
(2)biosystems informatics research group, centro de pesquisas rené rachou,
fundação oswaldo cruz (fiocruz), belo horizonte, minas gerais, brazil.
(3)department biochemistry, university cambridge, cambridge, united
kingdom.
(4)hospital julio muller, universidade federal de mato grosso, cuiabá, mato
grosso, brazil.

erratum in
    plos one. 2018 feb 1;13(2):e0192534.

although plasmodium vivax relapses classically associated hypnozoite
activation, proposed proportion cases due to
primaquine (pq) treatment failure caused polymorphisms cytochrome p-450 2d6
(cyp2d6). here, present evidence cyp2d6 polymorphisms implicated in
pq failure, reinforced findings genetically similar parasites,
and may explain number vivax relapses. using computational approach, these
polymorphisms predicted affect activity cyp2d6 changes 
the structural stability could lead disruption pq-enzyme
interactions. furthermore, pq co-administered chloroquine (cq),
we investigated whether cq-impaired metabolism cytochrome p-450 2c8 (cyp2c8)
could also contribute vivax recurrences. results show cyp2c8-mutated 
patients frequently relapsed early (<42 days) higher proportion of
genetically similar parasites, suggesting possibility recrudescence due to
cq therapeutic failure. results highlight importance pharmacogenetic
studies tool monitor efficacy antimalarial therapy.

doi: 10.1371/journal.pone.0160172 
pmcid: pmc4965052
pmid: 27467145  [indexed medline]

